Recombinant Human PD-L1

Human Programmed Death-Ligand 1 (PD-L1) is a protein that is a part of the immune checkpoint pathway which regulates the system used to balance the interaction between tumor cells and immune surveillance ¹. Unlike PD-1, which is mainly found on T-cells and acts as a receptor, PD-L1 is predominantly present on tumor cells and antigen-presenting cells. It serves as a mediator of immune tolerance by exploiting natural pathways that prevent autoimmunity. Tumors can evade the immune system and avoid detection by expressing PD-L1, inhibiting T-cell activation ² . Inflammatory cytokines in the tumor microenvironment further enhance this evasion strategy by increasing PD-L1 expression ³ . This highlights how tumors adapt and utilize the body's checkpoints for survival and growth. The complex involvement of PD-L1 in both tolerance and cancer immunoevasion emphasizes its significance as a target, for therapy. Blocking PD-L1 aims to dismantle the shield it provides to tumors allowing the immune system to regain its ability to eliminate cells ⁴ .

Human

Q15116

FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERT

Lyophilized

~40k Reduced Conditions

~25k

Reconstitute at 0.1-1 mg/ml using filtered deionized water. Gently mix by vortexing and/or inversion until fully dissolved. Centrifuge if necessary.

This lyophilized protein is stable for twelve months when stored at -20°C to -70°C. After aseptic reconstitution, this protein may be stored for one month at 2°C to 8°C or for three months at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Frozen Dry Ice

PD1

Human

Research Use Only

1. Yi M, Niu M, Xu L, Luo S, Wu K. J Hematol Oncol. 2021;14(1):10.
2. McDermott DF, Atkins MB. Cancer Medicine. 2013;2(5):662-673.
3. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. Journal of Cellular Physiology. 2019;234(2):1313-1325.
4. Dong Y, Sun Q, Zhang X. Oncotarget. 2017;8(2):2171-2186.